Nothing said here yet.
to join the conversation.
| Bergstrom Donald APresident, R&D | Sell | 2,252 | $41.9K | Wed, Oct 28 |
| Catinazzo ThomasChief Financial Officer | Sell | 1,469 | $27.4K | Wed, Oct 28 |
| Rahmer PeterSee remarks | Sell | 753 | $14.0K | Wed, Oct 28 |
| Patel SanjivPresident and CEO | Sell | 48,199 | $872.4K | Wed, Oct 7 |
| Catinazzo ThomasChief Financial Officer | Sell | 17,511 | $325.4K | Tue, Oct 6 |
| Catinazzo ThomasChief Financial Officer | Sell | 206 | $4.0K | Tue, Oct 6 |
| Patel SanjivPresident and CEO | Sell | 48,199 | $912.9K | Tue, Sep 8 |
| Catinazzo ThomasChief Financial Officer | Sell | 17,717 | $335.6K | Tue, Sep 8 |
| Bergstrom Donald APresident, R&D | Sell | 8,530 | $161.8K | Tue, Sep 8 |
| Rahmer PeterSee remarks | Sell | 4,508 | $90.3K | Wed, Aug 26 |
| SVF Pauling (Cayman) Ltd | Sell | 6,000,000 | $116.4M | Tue, Aug 25 |
| Patel SanjivPresident and CEO | Sell | 48,199 | $979.9K | Mon, Aug 17 |
Relay Therapeutics has seen its share price move sharply over the past year, which puts a fresh spotlight on whether that performance lines up with the strength of its balance sheet.
Relay Therapeutics (RLAY) has drawn investor attention after recent trading left the shares about 5% lower over the past month and roughly 13% weaker over the past 3 months.
WALTHAM, Mass., Sept.
Catinazzo's pre-arranged sale reduced his direct stake by 11%, but the insider still holds a significant amount of shares.
CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.
Relay Therapeutics (RLAY) reported second quarter 2026 results, with revenue of US$0.35 million and a net loss of US$83.71 million. This provides investors with fresh data on this clinical stage biotech stock. See our latest analysis for Relay Therapeutics.
Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near a new 3-year high.
Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patients expected to initiate in early 2027, subject to regulatory feedback Presented initial positive clinical data from Phase…
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc.